title: Immunotherapy of ovarian cancer. II. In vitro generation and characterization of lymphokine-activated killer T cells from the peripheral blood of recurrent ovarian cancer patients.
abstract: We examined the in vitro sensitivity of continuous ovarian cancer cells to lymphokine-activated killer T cells (T-LAK) alone or in combination with cytokines. Lymphocyte viability in T-LAK cultures generated from normal donors and ovarian cancer patients declined in the first 2 to 4 days; however, the remaining cells in these cultures maintained a constant rate of proliferation for long periods in vitro. These cells became 90-95% CD3+ TCR+ -alpha/beta T-cells after 7-10 days in culture. The T-LAK cells from normal donors and cancer patients expressed an equal ability to induce lysis of a panel of human target cells (NK-sensitive K562, NK-insensitive RAJI, and two human ovarian tumor lines, SKOV-3 and OVCAR-3), demonstrating that they are nongenetically restricted killers. Preincubation of either the effector or target cells with tumor necrosis factor or interferon-gamma or addition of these cytokines directly to cytolytic assays did not alter the degree of cell lysis in vitro. This is a method for generating large numbers of autologous, cytolytically active T-LAK cells from the blood of ovarian cancer patients that could be employed in adoptive intraperitoneal immunotherapy.
authors.affiliation: Department of Obstetrics and Gynecology, University of California, Irvine 92717.
authors.forename: J A
authors.initials: JA
authors.lastname: Lucci
authors.forename: A
authors.initials: A
authors.lastname: Manetta
authors.forename: F
authors.initials: F
authors.lastname: Cappuccini
authors.forename: E K
authors.initials: EK
authors.lastname: Ininns
authors.forename: C A
authors.initials: CA
authors.lastname: Dett
authors.forename: P
authors.initials: P
authors.lastname: DiSaia
authors.forename: R S
authors.initials: RS
authors.lastname: Yamamoto
authors.forename: M L
authors.initials: ML
authors.lastname: Berman
authors.forename: J
authors.initials: J
authors.lastname: Soopikian
authors.forename: G A
authors.initials: GA
authors.lastname: Granger
mesh_terms: D002455:Cell Division / Q000187:drug effects; D016207:Cytokines / Q000494:pharmacology; D003602:Cytotoxicity, Immunologic; D005260:Female; D006801:Humans; D016219:Immunotherapy, Adoptive; D007371:Interferon-gamma / Q000494:pharmacology; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000187:drug effects; D010051:Ovarian Neoplasms / Q000097:blood / Q000473:pathology / Q000628:therapy*; D010835:Phytohemagglutinins; D011994:Recombinant Proteins; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D013997:Time Factors; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
chemical_list: D016207:Cytokines; D010835:Phytohemagglutinins; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma